Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to ovarian cancer and may help the study of cancer in the future. PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.

Detailed Description
-----------------
OBJECTIVES: Determine the level of prostaglandin E_2 metabolite (PGE-M) in 24-hour urine samples collected prior to surgery or chemotherapy from patients with ovarian cancer. Determine cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression by western blot and immunohistochemistry (IHC) in ovarian tumor tissue samples and matched normal ovarian tissue samples, if available, from these patients. Correlate urine PGE-M levels with corresponding tissue COX-1 and COX-2 levels in urine and tissue samples from these patients. OUTLINE: This is a pilot study. Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of prostaglandin E_2 metabolite (PGE-M). Patients also undergo assessment of tissue obtained at the time of surgery, including ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for cyclooxygenase-1 and cyclooxygenase-2 expression.

Official Title
-----------------
Urine Prostaglandin-M(PGE-M) in Ovarian Cancer

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Genetic: protein expression analysis
* Other: immunohistochemistry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of known or suspected ovarian cancer Age greater than 17 years Exclusion Criteria: Pregnant or nursing Taking steroids or non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis. PRIOR CONCURRENT THERAPY: No concurrent chronic use of steroids or NSAIDs

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Known or suspected ovarian cancer<br>Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer | Genetic: protein expression analysis<br>* protein expression analysis<br>* Other names: protein expression analysis for PGE-M;Other: immunohistochemistry<br>* immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels<br>* Other names: immunohistochemistry staining methods;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prostaglandin E2 metabolite (PGE-M) levels in 24-hour urine samples | Patients will be collect their urine for 24 hours before they undergo any surgery or chemotherapy. Researchers will measure the amount of PGE-M in the urine. | Pre-surgical or chemotherapeutic treatment, over a 24-hour duration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COX-1 and COX-2 expression in ovarian tumor tissue and non-malignant tissue | COX-1 and COX-2 expression will be measured in samples of patients' malignant ovarian samples and matched non-malignant samples (the latter if available). | Day of surgery | 
| Correlation of urine PGE-M levels with tissue COX-1 and COX-2 levels | Patients' levels of urine PGE-M will be compared and contrasted with their levels of COX-1 and COX-2 in ovarian tumor tissue | After patients' surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent ovarian epithelial cancer, stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer